147 related articles for article (PubMed ID: 34893792)
21. Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus.
Marks AR; Pietrofesa RA; Jensen CD; Zebrowski A; Corley DA; Doubeni CA
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1692-8. PubMed ID: 26377195
[TBL] [Abstract][Full Text] [Related]
22. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
23. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
Allott EH; Abern MR; Gerber L; Keto CJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moorman PG; Freedland SJ
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):391-7. PubMed ID: 24100644
[TBL] [Abstract][Full Text] [Related]
24. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study.
Buchs AE; Silverman BG
Metabolism; 2011 Oct; 60(10):1379-85. PubMed ID: 21696791
[TBL] [Abstract][Full Text] [Related]
25. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
[TBL] [Abstract][Full Text] [Related]
26. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
27. Metformin use and prostate cancer risk: A meta-analysis of cohort studies.
Feng Z; Zhou X; Liu N; Wang J; Chen X; Xu X
Medicine (Baltimore); 2019 Mar; 98(12):e14955. PubMed ID: 30896668
[TBL] [Abstract][Full Text] [Related]
28. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer.
Park YM; Bookwalter DB; O'Brien KM; Jackson CL; Weinberg CR; Sandler DP
Ann Oncol; 2021 Mar; 32(3):351-359. PubMed ID: 33516778
[TBL] [Abstract][Full Text] [Related]
29. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
30. Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study.
Sluggett JK; Koponen M; Bell JS; Taipale H; Tanskanen A; Tiihonen J; Uusitupa M; Tolppanen AM; Hartikainen S
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31778170
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
32. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications.
Velicer CM; Dublin S; White E
Prostate Cancer Prostatic Dis; 2007; 10(1):46-51. PubMed ID: 17033617
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
[TBL] [Abstract][Full Text] [Related]
34. Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus.
Tseng CH
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680039
[No Abstract] [Full Text] [Related]
35. Metformin and the incidence of prostate cancer in patients with type 2 diabetes.
Azoulay L; Dell'Aniello S; Gagnon B; Pollak M; Suissa S
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):337-44. PubMed ID: 21148757
[TBL] [Abstract][Full Text] [Related]
36. Association of Metformin, Other Antidiabetic Medications, and Statins With Incidence of Colon Cancer in Patients With Type 2 Diabetes.
Erkinantti S; Marttila M; Sund R; Arffman M; Urpilainen E; Puistola U; Hautakoski A; Karihtala P; Läärä E; Jukkola A
Clin Colorectal Cancer; 2021 Jun; 20(2):e113-e119. PubMed ID: 33279415
[TBL] [Abstract][Full Text] [Related]
37. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.
Currie CJ; Poole CD; Jenkins-Jones S; Gale EA; Johnson JA; Morgan CL
Diabetes Care; 2012 Feb; 35(2):299-304. PubMed ID: 22266734
[TBL] [Abstract][Full Text] [Related]
38. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
39. The suggested chemopreventive association of metformin with prostate cancer in diabetic patients.
Goldberg H; Mohsin FK; Berlin A; Chandrasekar T; Wallis CJD; Klaassen Z; Ahmad AE; Saskin R; Kenk M; Saarela O; Kulkarni GS; Alibhai SMH; Fleshner N
Urol Oncol; 2021 Mar; 39(3):191.e17-191.e24. PubMed ID: 32951988
[TBL] [Abstract][Full Text] [Related]
40. Metformin use and survival after colorectal cancer: A population-based cohort study.
Mc Menamin ÚC; Murray LJ; Hughes CM; Cardwell CR
Int J Cancer; 2016 Jan; 138(2):369-79. PubMed ID: 26331456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
